新诊断的CD5阳性扩散型大B细胞淋巴瘤的治疗方法和结果:一个多机构的观察性研究

Yuma Nato1,2, Kana Miyazaki2, Dai Maruyama3

  • 1Department of Hematological Malignancies, Mie University Graduate School of Medicine, Tsu, Japan.

Hematological oncology
|February 12, 2025
PubMed
概括

剂量调整 (DA) -EPOCH-R和高剂量甲状腺酸盐 (HD-MTX) 化疗对CD5阳性扩散性大B细胞淋巴瘤 (CD5+DLBCL) 显示出有效的结果. 这种治疗提供了可管理的安全性,并可以预防CD5+DLBCL患者中中枢神经系统 (CNS) 复发.

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...